Interleukin-2 (IL-2), a cytokine that induces natural killer cells termed lymphokine-activated killer (LAK) cells, is in use as an anticancer agent. During IL-2 therapy, adverse effects, such as vasodilatation and hypotension, are common. Previous studies suggest that these effects are due to nitric oxide (NO). Therefore a model of IL-2-induced hyperdynamic response in sheep was developed to test the effect of pyridoxalated haemoglobin polyoxyethylene conjugate (PHP; a NO scavenger), which is currently in clinical development for the treatment of shock associated with systemic inflammatory response syndrome. Twelve female sheep were divided into four groups (n = 3 per group): sham control (Ringer's lactate solution), PHP alone (20 mg · kg −1 · h −1 for 96 h), IL-2 alone (recombinant human IL-2; 1 440 000 units/kg intravenously every 8 h) and a combination of PHP and IL-2. All of the sheep received Ringer's lactate solution to maintain haematocrit at baseline levels. The sheep had free access to food and water. A fall in the mean arterial pressure and systemic vascular resistance index by 20 % was observed in the IL-2 group, but not in the PHP + IL-2 group. The fluid requirement to maintain the haematocrit was higher in the IL-2 group (5 ml · kg −1 · h −1 ) than in the PHP + IL-2 group (4 ml · kg −1 · h −1 ). The sham group showed no changes in any of the parameters. Scavenging NO by PHP prevented the hyperdynamic reaction induced by IL-2 administration in sheep. This activity of PHP may prevent the early discontinuation of IL-2 therapy that results because of these adverse events.
INTRODUCTION
Interleukin-2 (IL-2) triggers the proliferation and activation of lymphokine-activated killer (LAK) cells, which develop the ability to lyse tumour cells. IL-2, either alone or in combination with LAK cells, is a treatment for advanced cancer, such as malignant melanoma, metastatic renal cell carcinoma or lung adenocarcinoma [1] [2] [3] [4] [5] . However, the toxicity of IL-2, when given at high doses, currently limits the broader application of this approach. The major dose-limiting toxicities are hypotension and 'third space' or vascular leak syndrome [6] [7] [8] . In this condition, pulmonary oedema, respiratory distress and peripheral oedema are frequently observed [4, 5, 9, 10] . The decrease in peripheral vascular resistance concomitant with decreased circulating plasma volume results in reduced central venous pressure and a marked fall in blood pressure [11] . These toxic adverse effects limit the duration of treatment and total dose of IL-2 administered [12] .
Many of the adverse affects of IL-2 therapy, including hypotension, vascular leak and myocardial depression, are similar to those observed in septic shock [6, 11] . Overproduction of nitric oxide (NO) plays a key role in the pathogenesis of haemodynamic instability and organ dysfunction in septic shock. It has been demonstrated previously [13] that IL-2 therapy results in increased release of NO metabolites in patients receiving IL-2 therapy. The haemodynamic effects observed in patients receiving IL-2 therapy have been attributed to excessive production of NO. Haemoglobins have been shown to have vasopressor activity in humans [14] , with the demonstrated effects mediated by haemoglobin inactivation of NO [15, 16] . Pyridoxalated haemoglobin polyoxyethylene conjugate (PHP) is a modified haemoglobin solution, which is prepared from outdated human erythrocytes by modification of deoxygenated stroma-free haemoglobin. PHP has now yielded promising results in Phase II clinical trials and is currently in a Phase III clinical trial for the treatment of shock associated with systemic inflammatory response syndrome (SIRS). Shock associated with SIRS is generally believed to be caused by an excessive production of NO [17] . It is proposed that the similar pathophysiology observed during IL-2 therapy may be ameliorated by a NO scavenger.
In the present study, IL-2-mediated toxicity was induced by administration of recombinant human (rh) IL-2 to sheep. The effect of a NO scavenger, PHP, on IL-2-mediated toxicity, including hyperdynamic effects and vascular leak, as well as an initial evaluation of the safety of this approach, were investigated.
MATERIALS AND METHODS

Materials
rhIL-2 (Proleukin ® ; Chiron, Emeryville, CA, U.S.A.) was used for the study. This compound is available for clinical use. PHP, the pyridoxalated and conjugated natural haemoglobin, was a gift from Apex Bioscience (Research Triangle Park, NC, U.S.A.). Other materials were of analytical grade.
Preparation of animals
This study was approved by the Animal Care and Use Committee of the University of Texas Medical Branch. All the animals were handled according to the guidelines established by the American Physiology Society and the National Institutes of Health. Adult female sheep (body weight, 30-40 kg) were surgically prepared under halothane anaesthesia. The right femoral artery was cannulated with a polyvinyl chloride catheter (18 gauge, 91 cm; Parke-Davis, Sandy, UT, U.S.A.) for continuous measurement of systemic arterial blood pressure and for intermittent sampling of arterial blood. A Swan-Ganz thermal dilution catheter (model 93A-131-7F; Edwards Laboratories, Irvine, CA, U.S.A.) was introduced through the right external jugular vein and advanced into the pulmonary artery for measurement of pulmonary arterial pressure (PAP). The catheter was also used for intermittent sampling of mixed venous (right atrium) blood, measurement of core body temperature and determination of cardiac output. A Silastic catheter (inner diameter 16 mm, outer diameter 31 mm; Dow Corning, Midland, MI, U.S.A.) was positioned in the left atrium through a left thoracotomy in the fifth intercostal space. This catheter was used for continuous measurement of left atrial pressure (LAP). A urinary catheter was inserted 24 h before IL-2 administration to measure the baseline creatinine clearance and urine volume, and urine levels of creatinine were measured every 24 h during the experiment.
Effect of various doses of IL-2 on physiological reactions in sheep
To model the hypotension induced by IL-2 injection, we first tested various doses of IL-2 to induce hypotension in sheep. Ten sheep were divided into five groups and the numbers of animals in each group are indicated in Table 1 . IL-2 was dissolved in 30 ml of saline and injected intravenously over 15 min using a Harvard infusion pump (model 55-1143; South Natick, MA, U.S.A.) every 8 h into the central venous (right atrium). Each animal group received IL-2 at a dose of 240 000-1 440 000 units/kg as shown in 
Effect of PHP on the IL-2-induced hyperdynamic reaction
To investigate the effect of PHP on the IL-2-induced hyperdynamic reaction, 12 animals were used. At 5 days after the surgical preparation, animals were randomly divided into four groups: sham group (no IL-2 or PHP; n = 3), PHP alone group (20 mg · kg −1 · h −1 , started 1 h before the IL-2 injection and continued throughout the 96 h study; n = 3), IL-2 alone group (1 440 000 units/kg, every 8 h; n = 3) and the combination of IL-2 + PHP group (n = 3). From the dose-response study, we found that animals receiving a high dose of IL-2 showed severe haemoconcentration. Therefore animals were resuscitated using Ringer's lactate solution. The dose of the fluid was based on the haematocrit levels and adjusted to maintain the baseline haematocrit. Initially, the infusion pump was set at 2 ml · kg −1 · h −1 and the setting was adjusted based on 4 h measurements of the haematocrit.
Nitrate/nitrite (NOx) assay in plasma
The plasma NO levels were evaluated by measuring the NO catabolites, NOx. For conversion of NOx into NO, the plasma samples were mixed with vanadium (III) and HCl at 90
• C in the NOx reduction assembly (ANTEK Model 745; Antek Instruments Inc., Houston, TX, U.S.A.). Thereafter NO was reacted with ozone in the reaction chamber of the chemiluminescent NO detector (ANTEK Model 7020), and the emitted light signal was recorded and calculated as the NO content (µM/l) by a special software [18] .
Lung wet-to-dry weight (W/D) ratio
At the autopsy, whole right lung was taken and was dissected free of non-pulmonary tissue and weighed. Subsequently, water was added (1 ml/g of tissue) and the tissue was homogenized. The homogenized sample was put into an oven (50
• C) for 1 week to obtain a constant dry weight. The bloodless W/D ratio was calculated using a reference blood sample, which was withdrawn at the autopsy [19] .
Statistics
The statistical software StatView5.0 (SAS Institute, Cary, NC, U.S.A.) was used to perform the analysis. Data are expressed as means + − S.E.M. ANOVA for multiple comparisons (two-way ANOVA) and Scheffé's post hoc test were used to compare data among the groups. Where appropriate, inter-group comparisons at individual time points were made using Student's t test for unpaired data. A P value < 0.05 was considered statistically significant. 
RESULTS
No animals died during this study. Endotoxin tests of the IL-2 solutions were negative (< 0.006 ng/ml).
Dose-response study
Two types of responses, acute and chronic, were observed following IL-2 injection. In acute responses, tachycardia was observed 5 min after IL-2 injection, continued for 15 min, and then returned to normal. Similarly, body temperature rose and then returned to baseline levels. In chronic responses, diarrhoea was observed 2-3 days after IL-2 therapy had started and continued until the end of the study. Only the highest dose (1 440 000 units/kg) of IL-2 induced chronic hypotension. The summary of the responses is shown in Table 1 . Arterial partial pressure of oxygen (Pao 2 )/fraction of inspired oxygen (Fio 2 ) ratio did not fall with any dose of IL-2 therapy (results not shown). The increase in plasma NOx was dose-dependent. Specifically, plasma NOx levels were unaffected at 480 000 units/kg, whereas 720 000 and 1 440 000 units/kg of IL-2 increased plasma NOx levels as shown in Figure 1 .
Effect of PHP on IL-2-induced hypotension
Since the dose-response study showed that the highest dose (1 440 000 units/kg) of IL-2 resulted in chronic hypotension and a marked increase in plasma levels of NOx, we investigated the effect of PHP with this dose of IL-2. As shown in Figure 2 (A), IL-2 alone resulted in a significant decrease in mean arterial pressure (MAP). In the IL-2 + PHP group, the fall in MAP did not occur and MAP was maintained at baseline levels. The PHP alone group did not show a significant change in MAP during the 96 h study period. PAP increased in all of the groups compared with the baseline levels ( Figure 2B ), but there was no difference between the groups. LAP rose in the IL-2 group at 48-84 h time points (P < 0.05 compared with 
Figure 3 SVRI (A) and CI (B)
A fall in SVRI was observed in the IL-2-treated group, whereas PHP alone increased SVRI significantly. Data are expressed as means + − S.E.M. * P < 0.05 compared with baseline.
baseline; Figure 2C) ; however, there were no statistical differences between the other groups. Haematocrit was maintained at baseline levels by adjusting the infusion rate of Ringer's lactate solution and there was no difference between the groups ( Figure 2D ). Systemic vascular resistance index (SVRI) significantly decreased in the IL-2 group ( Figure 3A) . In contrast, the PHP group showed a significant increase in SVRI.
The IL-2 + PHP group showed no significant decrease in SVRI, effectively reversing the effect of IL-2 on SVRI. There was a slight increase in cardiac index (CI) in the IL-2-treated group ( Figure 3B ). On the other hand, the PHP group showed a significant decrease in CI. This decrease was, in the most part, due to a fall in heart rate, which may be a normal baroreceptor response to vasoconstriction. CI was slightly increased by IL-2, but was not significantly affected when combined with PHP.
Lung W/D ratio
In order to assess vascular leak, lung water content was evaluated by bloodless lung W/D ratio. There were no statistically significant differences between groups for this variable. IL-2 alone tended to increase the lung W/D ratio (4.88 + − 0.27 in sham-treated group compared with 5.18 + − 0.36 in the IL-2 alone group). There was a trend towards reversing this increase in the PHP + IL-2-treated group (4.97 + − 0.13; not statistically different compared with the IL-2 group). PHP alone did not change the lung W/D ratio (4.70 + − 0.09).
Fluid requirement
The rate of fluid resuscitation was adjusted by monitoring haematocrit levels ( Figure 2D) , and the amount of fluid needed to keep the haematocrit stable was determined. Basically, all animals received 2 ml · kg −1 · h −1 of Ringer's lactate solution. Based on the haematocrit levels, which were measured every 4 h, we adjusted the infusion rate. For instance, when the haematocrit levels rose three points (which is approx. 10 % of baseline value), the rate was increased by 1 ml · kg −1 · h −1 . In contrast, when
Figure 4 Rate of fluid resuscitation required to maintain the baseline haematocrit levels at various time points
Initially, the pump was set at 2 ml · kg −1 · h −1 and haematocrit levels were checked every 4 h. The settings were then adjusted to maintain the baseline level of haematocrit during the experiment. IL-2-treated group required higher doses of fluid resuscitation especially at 48-96 h of IL-2 administration. Data are expressed as means + − S.E.M. * P < 0.05 compared with baseline.
the haematocrit level was three points lower, the infusion rate was decreased by 1 ml · kg −1 · h −1 . The range used was from 2-7 ml · kg −1 · h −1 . As shown in Figure 4 , a higher dose of fluid injection was needed in the IL-2-treated group. The IL-2 + PHP group showed a trend for less fluid requirement than the IL-2 group, but the difference between groups was not statistically significant. PHP alone had no effect on fluid requirements.
Changes in blood count
There was a trend for reducing lymphocyte numbers with time in the IL-2-treated group as well as IL-2 + PHP group. However, no statistical differences were found compared with baseline levels or between the groups ( Table 2 ). The combination of PHP with IL-2 showed
Table 2 Effect of PHP and IL-2 on blood counts
Complete blood counts were analysed by an automated haemocytometer calibrated for sheep. Data are expressed as means + − S.E.M. There were no statistical differences compared with baseline values or between the treatment groups. almost the same trend as the IL-2 group. Erythrocyte and platelet counts did not change during the study (Table 2 ).
Blood chemistry
Liver enzymes (aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase and total bilirubin), electrolytes (sodium, potassium, magnesium, calcium, chloride), glucose, creatinine, blood urea nitrogen, troponin T and prothrombin time were analysed during the study. None of these variables changed significantly during the study and there were no statistical differences between the groups (Table 3) .
DISCUSSION
Adoptive immunotherapy, the administration of IL-2, leads to tumour regression in some patients with advanced cancer [20] . Although this new therapeutic modality offers hope for the future, a multitude of toxicities limit the total dose and duration of the therapy. The toxic side-effects include severe hypotension resulting in a decrease in systemic vascular resistance and hypoperfusion of vital organs, and in the development of vascular leak syndrome [6] [7] [8] 10, 21] . Rosenstein et al. [22] reported that the vascular leakage is dependent on the dose and duration of IL-2 treatment. There are several animal models using rhIL-2. Among these, sheep show very similar responses to those seen in humans, especially with respect to cardiopulmonary effects [23, 24] . Jesmok and Gunther [25] demonstrated in the ovine model that most of the pulmonary vascular leak syndrome effects appear to be secondary to a decreased systemic resistance and an increase in capillary permeability. In the present study, hypotension as well as a decrease in SVRI was observed several days after administration of IL-2, which is consistent with the previous reports.
Table 3 Effect of PHP and IL-2 on blood chemistry
Data are expressed as means + − S.E.M. No significant changes were observed in each variable during the study. AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen. IL-2 is known to enhance lymphocyte mitogenesis and lymphocyte cytotoxicity [20] . IL-2 also induces proliferation of LAK and natural killer cells and production of interferon-γ . These responses play a central role in cell-mediated immune responses directed against cancer cells [20] . IL-2 has demonstrated anticancer activity in preclinical and clinical trials [20] . High-dose intravenous bolus administration of IL-2 produced durable complete remission in approx. 5-10 % of patients with metastatic renal cell carcinoma and malignant melanoma [26] . During IL-2 treatment, hypotension is frequently observed (approx. 70 % of patients suffered grade 3 or 4 hypotension), and IL-2 administration is often discontinued because of hypotension. Diarrhoea, chill and fever are other complications of IL-2 therapy and are observed in 50-60 % of patients. This investigation was designed to test whether PHP, a NO scavenger, would diminish these IL-2-dose-limiting adverse effects. It was also critical to establish that there were no unexpected drug interactions when PHP was used concomitantly with IL-2.
PHP is a chemically modified haemoglobin, which has a high affinity for NO [27] . In a septic model in sheep, it was effective in preventing the NO-mediated hyperdynamic reaction as well as hypotension [27] .
In the present study, we found that only the highest dose of IL-2 resulted in chronic hypotension. MAP and systemic vascular resistance gradually decreased with time. PHP, presumably through an NO-scavenging mechanism, attenuated these changes. When PHP was given alone without IL-2, systemic vascular resistance increased significantly and the CI decreased significantly.
This decrease in cardiac output may be due to a normal baroreceptor response and was not associated with any symptoms of hypoperfusion or organ damage. This suggests that scavenging the NO released from endothelial cells results in vasoconstriction in the systemic circulation.
Fluid was administered to maintain baseline haematocrit levels ( Figure 2D ). As shown in Figure 4 , the IL-2-treated group required a higher amount of fluid to maintain the baseline haematocrit levels, probably due to a loss of intravascular fluid into interstitial tissues resulting from increased vascular permeability.
Systemic vasodilatation may also be a cause of the high fluid requirement. Since systemic vascular resistance was attenuated by PHP, it is possible that prevention of systemic vasodilatation, especially dilatation of the capacitance vessels, is one of the reasons for the attenuation of the fluid requirement. High-dose IL-2 resulted in severe watery diarrhoea (Table 1) . PHP did not attenuate diarrhoea, which may explain why PHP only partially reversed the fluid requirement.
Mier et al. [28] demonstrated that tumour necrosis factor may play a role in the fever and shock-like state induced by the administration of high-dose IL-2. They found that the administration of dexamethasone increased the maximum tolerated dose of IL-2 approx. 3-fold and markedly reduced the hypotension and organ dysfunction ordinarily observed in these patients. However, there is a concern regarding this approach for the treatment of cancer, because the mechanism of action of IL-2 is mediated by the induction of natural killer cells and interferon-γ and steroids inhibit mediation of these effects. Thus the combination of corticosteroids with IL-2 might inhibit the anticancer effect of IL-2. As shown in Table 2 , the trend towards decreased lymphocyte count was observed by IL-2 therapy (P = 0.06 at 72 h in the IL-2-treated group). In contrast, the trend towards a decreasing lymphocyte count in the PHP-treated group was less, suggesting that PHP may not influence lymphocyte activation much.
The present study demonstrates that PHP administration diminishes vascular leakage syndrome and the hyperdynamic effects induced by IL-2 treatment in sheep. Complete evaluation of the efficacy of PHP in the present study was limited by the cost of IL-2, prohibiting a larger sample size. The toxicity of IL-2, including dose-limiting haemodynamic side effects, often results in patient hospitalization in intensive care units and a decrease in the planned number of IL-2 doses. Reducing this toxicity may result in higher dosing regimens and more complete courses of therapy to be administered, with the potential for increased anticancer activity. Since PHP did not show any adverse effects and is now in a Phase III clinical trial for the treatment of shock associated with SIRS, it may prove useful as an adjunct to IL-2 chemotherapy and merits further study.
